期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Development and validation of a model to determine risk of refractory benign esophageal strictures 被引量:1
1
作者 Qing Lu Tian-Tian Lei +5 位作者 yi-lan wang Hai-Lin Yan Bo Lin Lin-Lin Zhu Hong-Sheng Ma Jin-Lin Yang 《World Journal of Clinical Cases》 SCIE 2019年第13期1623-1633,共11页
BACKGROUND Current research has identified several risk factors for refractory benign esophageal strictures (RBES), but research is scarce on the prediction of RBES in benign esophageal strictures patients. Meanwhile,... BACKGROUND Current research has identified several risk factors for refractory benign esophageal strictures (RBES), but research is scarce on the prediction of RBES in benign esophageal strictures patients. Meanwhile, the long-term outcomes of RBES remain unclear. The aim of this study was to develop and validate a model to determine the progression of RBES in patients with benign esophageal strictures. And we also explored the long-term outcomes and safety in patients with RBES. AIM To develop and validate a model to determine the progression of RBES in patients with benign esophageal strictures, based on the demographic data and endoscopic findings. METHODS A total of 507 benign esophageal stricture patients treated by dilation alone or in combination with stenting were retrospectively enrolled between January 2009 and February 2018. The primary outcome was to establish a risk-scoring model predicting RBES in benign esophageal strictures. The secondary outcome was to explore the clinical effectiveness and adverse events in patients with RBES. RESULTS In the study, age, etiology, and number and length of strictures were the independent risk factors for the refractory performance of benign esophageal strictures. According to risk factors of benign esophageal strictures, a risk-scoring model for predicting RBES in benign esophageal strictures was established: The risk score ranged from 0 to 8 points, and the risk scores were divided into low risk (0-2 points), intermediate risk (3-5 points), and high risk (6-8 points). The proportions of RBES in the corresponding risk categories were 1.0%, 12.2%, and 76.0%, respectively. Among 507 patients, 57 had RBES (39 males;median age, 60 years). The success rate of dilation treatment (51.2%, 21/41) was higher than that of stent placement (37.5%, 6/16). CONCLUSION In this study, 11.3%(57/507) patients had RBES at our hospital. The risk-scoring model predicting RBES in benign esophageal strictures could predict the longterm outcome of patients with strictures ahead. 展开更多
关键词 REFRACTORY BENIGN ESOPHAGEAL STRICTURES ESOPHAGEAL DILATION ESOPHAGEAL STENTS Long-term outcomes Retrospective analysis
下载PDF
Serum non-high-density lipoprotein cholesterol level is increased in Chinese patients with nonalcoholic fatty liver disease 被引量:1
2
作者 Si-Yu Shao yi-lan wang +1 位作者 Li-Min Feng Ying Zhao 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2020年第6期602-604,共3页
To the Editor:Nonalcoholic fatty liver disease(NAFLD)is a growing public health problem globally.Although the primary liver pathology in NAFLD patients is associated with an increased risk of overall mortality,the maj... To the Editor:Nonalcoholic fatty liver disease(NAFLD)is a growing public health problem globally.Although the primary liver pathology in NAFLD patients is associated with an increased risk of overall mortality,the majority of deaths in NAFLD patients are due to the cardiovascular disease(CVD)[1].With the change of lifestyle,the prevalence of NAFLD in China is increasing and patients tend to be younger[2].A relevant epidemiological survey has shown that the prevalence of NAFLD in adults is estimated to be 12%–24%in Asia[3].Non-high-density lipoprotein cholesterol(non-HDL-C)refers to the sum of all cholesterol subtracts high-density lipoprotein cholesterol(HDL-C),which can more comprehensively reflect the comprehensive metabolic changes of lipoproteins including low-density lipoprotein cholesterol(LDL-C),intermediate-density lipoprotein cholesterol(IDL-C),and very-low-density lipoprotein cholesterol(VLDL-C)[4].Recently,NAFLD that often coexists with dyslipidemia has been identified as a major modifiable risk factor of CVD,and non-HDL-C has become a new biomarker for assessing and predicting the risk of CVD[4]. 展开更多
关键词 patients CHOLESTEROL LIPOPROTEIN
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部